Trials / Unknown
UnknownNCT01122225
Neutrophile Gelatinase Associated Lipocalin Evaluation in Septic Acute Kidney Injury
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- Université Victor Segalen Bordeaux 2 · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Acute kidney injury (AKI) is a major organ failure in septic shock. Current medical tests (serum creatinine and urea) cannot identify AKI until approximately 48 hours after it occurs. Neutrophil gelatinase-associated lipocalin (NGAL) may be able to predict ischemic AKI more effectively and faster than serum creatinine and urea levels. The purpose of this study is to take a blood sample from patients at admission and then at 24 and 48 hours after to test their plasma for NGAL and compare the NGAL levels to their creatinine and urea levels. The investigators hypothesize that NGAL is an earlier marker to classify the kidney failure as acute tubular necrosis or pre-renal azotemia than creatinine and urea.
Detailed description
Primary Outcome Measures: To correlate elevated serum NGAL with the diagnosis of intrinsic acute kidney injury in septic shock Secondary Outcome Measures : To compare serum NGAL with serum creatinine, serum urea and urine output in septic AKI Death within the intensive care unit Death from all causes at 28 days after inclusion
Conditions
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2010-05-01
- Completion
- 2010-06-01
- First posted
- 2010-05-13
- Last updated
- 2010-05-31
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01122225. Inclusion in this directory is not an endorsement.